Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
-1.35%
$499.03
0% positive prob.
5-Day Prediction
-2.21%
$494.67
0% positive prob.
20-Day Prediction
-1.38%
$498.86
0% positive prob.
SEC 8-K filings with transcript text
Jan 27, 2026 · 100% conf.
1D
-1.35%
$499.03
Act: -2.89%
5D
-2.21%
$494.67
Act: -1.31%
20D
-1.38%
$498.86
Act: +6.87%
8-K
false000086073000008607302026-01-272026-01-27
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 27, 2026
HCA Healthcare, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-11239
27-3865930
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza
Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (615) 344-9551
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
HCA
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On January 27, 2026, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2025, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On January 27, 2026, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2025, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On January 27, 2026, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $10 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise.
On January 27, 2026, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.78 per share of the Company’s common stock. The dividend will be paid on March 31, 2026 to stockholders of record at the close of business on March 17, 2026. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
Exhibit 99.1
Press Release, dated January 27, 2026
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
January 27, 2026
By:
/s/ Michael A. Marks
Michael A. Marks Executive Vice President and Chief Financial Officer
Oct 24, 2025
8-K
false000086073000008607302025-10-242025-10-24
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 24, 2025
HCA Healthcare, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-11239
27-3865930
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza
Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (615) 344-9551
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
HCA
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On October 24, 2025, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2025, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On October 24, 2025, the Company issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2025, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On October 24, 2025, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.72 per share of the Company’s common stock. The dividend will be paid on December 29, 2025 to stockholders of record at the close of business on December 15, 2025. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
Exhibit 99.1
Press Release, dated October 24, 2025
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
October 24, 2025
By:
/s/ Michael A. Marks
Michael A. Marks Executive Vice President and Chief Financial Officer
Jul 25, 2025
8-K
0000860730false00008607302025-07-252025-07-25
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 25, 2025
HCA Healthcare, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-11239
27-3865930
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza
Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (615) 344-9551
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
HCA
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On July 25, 2025, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2025, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On July 25, 2025, the Company issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2025, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On July 25, 2025, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.72 per share of the Company’s common stock. The dividend will be paid on September 30, 2025 to stockholders of record at the close of business on September 16, 2025. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
Exhibit 99.1
Press Release, dated July 25, 2025
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
July 25, 2025
By:
/s/ Michael A. Marks
Michael A. Marks Executive Vice President and Chief Financial Officer
Apr 25, 2025
8-K
false000086073000008607302025-04-252025-04-25
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 25, 2025
HCA Healthcare, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-11239
27-3865930
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza
Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (615) 344-9551
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
HCA
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On April 25, 2025, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2025, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On April 25, 2025, the Company issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2025, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On April 25, 2025, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.72 per share of the Company’s common stock. The dividend will be paid on June 30, 2025 to stockholders of record at the close of business on June 16, 2025. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
Exhibit 99.1
Press Release, dated April 25, 2025
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
April 25, 2025
By:
/s/ Michael A. Marks
Michael A. Marks Executive Vice President and Chief Financial Officer
Jan 24, 2025
8-K
false000086073000008607302025-01-242025-01-24
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 24, 2025
HCA Healthcare, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
001-11239
27-3865930
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza
Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (615) 344-9551
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
HCA
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On January 24, 2025, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2024, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On January 24, 2025, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2024, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On January 24, 2025, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $10 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise.
On January 24, 2025, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.72 per share of the Company’s common stock. The dividend will be paid on March 31, 2025 to stockholders of record at the close of business on March 17, 2025. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
Exhibit 99.1
Press Release, dated January 24, 2025
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
January 24, 2025
By:
/s/ Michael A. Marks
Michael A. Marks Executive Vice President and Chief Financial Officer
Oct 25, 2024
8-K
false000086073000008607302024-10-252024-10-25
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 25, 2024
HCA Healthcare, Inc. (Exact name of Registrant as Specified in Its Charter)
Delaware
1-11239
27-3865930
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza
Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: 615 344-9551
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $0.01 par value per share
HCA
New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On October 25, 2024, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2024, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On October 25, 2024, the Company issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2024, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On October 25, 2024, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.66 per share of the Company’s common stock. The dividend will be paid on December 27, 2024 to stockholders of record at the close of business on December 13, 2024. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
Exhibit 99.1
Press Release, dated October 25, 2024
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
October 25, 2024
By:
/s/ Michael A. Marks
Michael A. Marks Executive Vice President and Chief Financial Officer
Jul 23, 2024
8-K
false 0000860730 0000860730 2024-07-23 2024-07-23
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): July 23, 2024
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On July 23, 2024, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2024, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On July 23, 2024, the Company issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2024, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On July 23, 2024, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.66 per share of the Company’s common stock. The dividend will be paid on September 30, 2024 to stockholders of record at the close of business on September 16, 2024. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated July 23, 2024
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ Michael A. Marks
Michael A. Marks Executive Vice President and Chief Financial Officer
Date: July 23, 2024
Apr 26, 2024
8-K
false 0000860730 0000860730 2024-04-26 2024-04-26
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): April 26, 2024
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On April 26, 2024, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2024, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On April 26, 2024, the Company issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2024, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On April 26, 2024, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.66 per share of the Company’s common stock. The dividend will be paid on June 28, 2024 to stockholders of record at the close of business on June 14, 2024. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated April 26, 2024
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: April 26, 2024
Jan 30, 2024
Form 8-K
false 0000860730 0000860730 2024-01-24 2024-01-24
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): January 30, 2024 (January 24, 2024)
HCA Healthcare, Inc. (Exact Name of Registrant as Specified in its Charter)
Delaware
001-11239
27-3865930
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(I.R.S. Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code) (615) 344-9551 (Registrant’s Telephone Number, including Area Code) Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On January 30, 2024, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2023, the text of which is set forth as Exhibit 99.1.
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Retirement of William B. Rutherford as Executive Vice President and Chief Financial Officer of the Company On January 24, 2024, William B. Rutherford notified the Company of his intent to retire from his position as Executive Vice President and Chief Financial Officer, effective May 1, 2024. A copy of the press release issued by the Company relating to Mr. Rutherford’s retirement is attached hereto as Exhibit 99.1 and incorporated herein by reference. Appointment of Michael A. Marks as Executive Vice President and Chief Financial Officer of the Company In conjunction with Mr. Rutherford’s retirement, on January 30, 2024, the Company announced that Michael A. Marks, age 54, will succeed Mr. Rutherford as Executive Vice President and Chief Financial Officer, effective May 1, 2024. Mr. Marks joined HCA Healthcare in 1996 and has served as Senior Vice President — Finance since January 1, 2023. Mr. Marks previously served as Vice President — Financial Operations Support from March 2021 to December 2022. Prior to that time, he served as CFO of the National Group from December 2008 to February 2021 and CFO of the West Florida Division from January 2006 to November 2008. Beginning on the effective date of Mr. Marks’ appointment, the Compensation Committee (the “Committee”) of the Board of Directors of the Company has approved a base salary of $900,000 for Mr. Marks. In addition, in connection with his appointment, the Committee determined to grant Mr. Marks a long-term equity incentive award with a total target grant date value of $2,000,000 (the “Equity Award”), with fifty percent (50%) of the target award in the form of stock appreciation rights which vest over four years and the other fifty percent (50%) of the target award in the form of performance share units which vest upon achievement of a cumulative three year earnings per share goal, in each case, in accordance with the terms and conditions of the award agreements and the 2020 Stock Incentive Plan for Key Employees of HCA Healthcare, Inc. and its Affiliates. The Equity Award is anticipated to be granted on or about May 1, 2024. Other than with respect to the foregoing, Mr. Marks is not a party to any material plan, contract or arrangement with the Company other than the HCA Supplemental Executive Retirement Plan and other plans and arrangements generally available to all Executive Vice President-level officers of the Company and as disclosed in the Co
Oct 24, 2023
Form 8-K
false 0000860730 0000860730 2023-10-24 2023-10-24
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): October 24, 2023
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On October 24, 2023, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2023, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On October 24, 2023, the Company issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2023, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On October 24, 2023, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.60 per share of the Company’s common stock. The dividend will be paid on December 28, 2023 to stockholders of record at the close of business on December 14, 2023. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated October 24, 2023
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: October 24, 2023
Jul 27, 2023
Form 8-K
false 0000860730 0000860730 2023-07-27 2023-07-27
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): July 27, 2023
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On July 27, 2023, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2023, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On July 27, 2023, the Company issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2023, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On July 27, 2023, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.60 per share of the Company’s common stock. The dividend will be paid on September 29, 2023 to stockholders of record at the close of business on September 15, 2023. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated July 27, 2023
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: July 27, 2023
Apr 21, 2023
Form 8-K
false 0000860730 0000860730 2023-04-21 2023-04-21
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): April 21, 2023
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On April 21, 2023, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2023, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On April 21, 2023, the Company issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2023, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On April 21, 2023, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.60 per share of the Company’s common stock. The dividend will be paid on June 30, 2023 to stockholders of record at the close of business on June 16, 2023. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated April 21, 2023
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: April 21, 2023
Jan 27, 2023
Form 8-K
false 0000860730 0000860730 2023-01-27 2023-01-27
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): January 27, 2023
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-11239
27-3865930
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code) Registrant’s Telephone Number, including Area Code: (615) 344-9551 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On January 27, 2023, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2022, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On January 27, 2023, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2022, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On January 27, 2023, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $3 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise. On January 27, 2023, the Company also announced that its Board of Directors had declared a quarterly cash dividend of $0.60 per share of the Company’s common stock. The dividend will be paid on March 31, 2023 to stockholders of record at the close of business on March 17, 2023. Item 9.01. Financial Statements and Exhibits. (d) Exhibits:
Exhibit 99.1
Press Release, dated January 27, 2023
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
By:
/s/ William B. Rutherford
William B. Rutherford
Executive Vice President and Chief Financial Officer
Date: January 27, 2023
Oct 21, 2022
Form 8-K
false 0000860730 0000860730 2022-10-21 2022-10-21
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): October 21, 2022
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On October 21, 2022, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2022, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On October 21, 2022, the Company issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2022, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On October 21, 2022, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.56 per share of the Company’s common stock. The dividend will be paid on December 28, 2022 to stockholders of record at the close of business on December 14, 2022. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated October 21, 2022
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: October 21, 2022
Jul 22, 2022
Form 8-K
false 0000860730 0000860730 2022-07-22 2022-07-22
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): July 22, 2022
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On July 22, 2022, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2022, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On July 22, 2022, the Company issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2022, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On July 22, 2022, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.56 per share of the Company’s common stock. The dividend will be paid on September 30, 2022 to stockholders of record at the close of business on September 16, 2022. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated July 22, 2022
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: July 22, 2022
Apr 22, 2022
Form 8-K
false 0000860730 0000860730 2022-04-22 2022-04-22
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): April 22, 2022
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On April 22, 2022, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2022, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On April 22, 2022, the Company issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2022, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On April 22, 2022, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.56 per share of the Company’s common stock. The dividend will be paid on June 30, 2022 to stockholders of record at the close of business on June 16, 2022. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated April 22, 2022
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: April 22, 2022
Jan 27, 2022
Form 8-K
false 0000860730 0000860730 2022-01-24 2022-01-24
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d)
Date of Report (Date of earliest event reported): January 27, 2022 (January 24, 2022)
(Exact Name of Registrant as Specified in its Charter)
Delaware
001-11239
27-3865930
(State or Other Jurisdiction
of Incorporation)
(Commission File Number)
(IRS Employer
Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of Principal Executive Offices)
(Zip Code) Registrant’s Telephone Number, including Area Code: (615) 344-9551 Not Applicable (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On January 27, 2022, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2021, the text of which is set forth as Exhibit 99.1. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 24, 2022, the Company’s Board of Directors (the “Board”), based on the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Andrea B. Smith to the Company’s Board effective January 26, 2022, increasing the number of directors on the Board from 10 to 11. Ms. Smith will serve on the Board’s Audit and Compliance Committee and Patient Safety and Quality of Care Committee. Ms. Smith was appointed to the Board pursuant to the Company’s Amended and Restated Certificate of Incorporation, which provides that a majority of directors on the Board may determine the number of directors which shall constitute the Board and that the Board may fill a newly created directorship resulting from any increase in the number of directors on the Board. There is no arrangement or understanding between Ms. Smith and any other person pursuant to which Ms. Smith was selected as a director on the Board, nor is Ms. Smith a member of the family of any executive officer of the Company or of any other director on the Board. There have been no transactions, proposed or otherwise, in which Ms. Smith participated or will participate that would be required to be disclosed herein pursuant to Item 404(a) of Regulation S-K. Ms. Smith will participate in the compensation program the Company maintains for its non-management directors, which compensation program was described in the Proxy Statement the Company filed with the Securities and Exchange Commission on March 19, 2021. A copy of the press release issued by the Company announcing Ms. Smith’s appointment to the Board is attached hereto as Exhibit 99.2 and incorporated herein by reference. Item 7.01. Regulation FD Disclosure. On January 27, 2022, the Company issued a press release announcing, among other matters, its results of operations for the fourth quarter and year ended December 31, 2021, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On January 27, 2022, the Company announced that its Board of Directors had authorized an additional share repurchase program for up to $8 billion of the Company’s outstanding common stock. Repurchases will be made in accordance with applicable securities laws from time to time in the open market, through privately negotiated transactions, or otherwise. On January 27, 2022, the Company also announced that its Board of Directors had declared a quarterly cash dividend of $0.56 per share o
Oct 22, 2021
Form 8-K
false 0000860730 0000860730 2021-10-22 2021-10-22
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): October 22, 2021
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On October 22, 2021, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2021, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On October 22, 2021, the Company issued a press release announcing, among other matters, its results of operations for the third quarter ended September 30, 2021, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On October 22, 2021, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.48 per share of the Company’s common stock. The dividend will be paid on December 29, 2021 to stockholders of record at the close of business on December 14, 2021. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated October 22, 2021
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: October 22, 2021
Jul 20, 2021
8-K
false 0000860730 0000860730 2021-07-20 2021-07-20
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): July 20, 2021
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On July 20, 2021, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2021, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On July 20, 2021, the Company issued a press release announcing, among other matters, its results of operations for the second quarter ended June 30, 2021, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On July 20, 2021, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.48 per share of the Company’s common stock. The dividend will be paid on September 30, 2021 to stockholders of record at the close of business on September 16, 2021. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated July 20, 2021
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: July 20, 2021
Apr 22, 2021
Form 8-K
false 0000860730 0000860730 2021-04-22 2021-04-22
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): April 22, 2021
(Exact name of registrant as specified in its charter)
Delaware
001-11239
27-3865930
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
One Park Plaza, Nashville, Tennessee
37203
(Address of principal executive offices)
(Zip Code) Registrant’s telephone number, including area code: (615) 344-9551 Not Applicable (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
HCA
New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On April 22, 2021, HCA Healthcare, Inc. (the “Company”) issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2021, the text of which is set forth as Exhibit 99.1. Item 7.01. Regulation FD Disclosure. On April 22, 2021, the Company issued a press release announcing, among other matters, its results of operations for the first quarter ended March 31, 2021, the text of which is set forth as Exhibit 99.1. Item 8.01. Other Events. On April 22, 2021, the Company announced that its Board of Directors had declared a quarterly cash dividend of $0.48 per share of the Company’s common stock. The dividend will be paid on June 30, 2021 to stockholders of record at the close of business on June 16, 2021. Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
Exhibit 99.1
Press Release, dated April 22, 2021
Exhibit 104
Cover Page Interactive Data File (embedded within the Inline XBRL document).
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
/s/ William B. Rutherford
William B. Rutherford Executive Vice President and Chief Financial Officer
Date: April 22, 2021
This page provides HCA Healthcare Inc. (HCA) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on HCA's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.